Logo Logo Logo Logo Logo
  • Company
    • Company Overview
    • Board of Directors
    • Executive Team
    • Advisory Board
  • Pipeline
    • Product Overview
    • AR-301 (Tosatoxumab)
    • AR-320 (Suvratoxumab)
    • AR-501 (Panaecin™)
    • AR-701 (COVID-19 mAb)
    • Preclinical
      • AR-401
    • Out-licensed Products
      • AR-105 (Aerucin®)
      • AR-101 (AerumabTM)
      • AR-201
  • TECHNOLOGY
    • Technology Overview
    • ⅄PEXTM
    • MabIgX®
    • Therapeutic Targets
      • HAP / VAP
      • VAP Prevention
      • Cystic Fibrosis
      • COVID-19 Disease
    • Welcome
    • Corporate Governance
      • Board of Directors
      • Board Committees
    • News Releases
    • SEC Filings
    • Stock Information
      • Historical Stock Price
      • Analyst Coverage
    • Events and Webcasts
    • Publications and Posters
    • Investor Alerts
    • Investor Inquiries
  • Contact Us
    • Contact Us
    • Careers
  • News
  • Company
    • Company Overview
    • Board of Directors
    • Executive Team
    • Advisory Board
  • Pipeline
    • Product Overview
    • AR-301 (Tosatoxumab)
    • AR-320 (Suvratoxumab)
    • AR-501 (Panaecin™)
    • AR-701 (COVID-19 mAb)
    • Preclinical

      • AR-401
    • Out-licensed Products

      • AR-105 (Aerucin®)
      • AR-101 (AerumabTM)
      • AR-201
  • TECHNOLOGY
    • Technology Overview
    • ⅄PEXTM
    • MabIgX®
    • Therapeutic Targets

      • HAP / VAP
      • VAP Prevention
      • Cystic Fibrosis
      • COVID-19 Disease
    • Welcome
    • Corporate Governance
      • Board of Directors
      • Board Committees
    • News Releases
    • SEC Filings
    • Stock Information
      • Historical Stock Price
      • Analyst Coverage
    • Events and Webcasts
    • Publications and Posters
    • Investor Alerts
    • Investor Inquiries
  • Contact Us
    • Contact Us
    • Careers
  • News
Search:
 

Sitemap

COMPANY

  • Overview
  • Board of Directors
  • Executive Team 
  • Advisory Board

 

PIPELINE

  • Overview
  • AR-301 (Salvecin®)
  • AR-101 (AerumabTM)
  • AR-501 (PanaecinTM)

 

PRECLINICAL

  • AR-201
  • AR-401

 

TECHNOLOGY

  • Overview
  • MabIgX®

 

THERAPEUTICS TARGETS

  • HABP / VABP
  • Cystic Fibrosis

 

NEWS & EVENTS

  • Press Releases
  • Events

 

INVESTORS + MEDIA

  • Publications
  • Email Alerts

 

Contact Us

Contact
Aridis Pharmaceuticals Inc.
983 University Avenue Suite B
Los Gatos, CA 95032
Phone: 408-385-1742
Fax: 408-356-9548

 

 

Additional Information

Site Map
Privacy Policy
Financial Conflict of Interest Policy

News Releases

.

Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update Nov 3, 2023 04:15 PM

.

Aridis Pharmaceuticals Announces $2 Million Offering Aug 2, 2023 8:17 AM

social media icon social media icon

© 2022 Aridis Pharmaceuticals Inc. All rights reserved.